Clinical trial · Interventional
Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
Stem Cell Augmented, Elutriated Grafts for Allogeneic Bone Marrow Transplantation
NCT00003538CI-TRIAL-00014401completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. Sometimes the transplanted cells can make an immune response against the body's normal tissues. Stem cells that have been treated in the laboratory to remove lymphocytes may prevent this from happening. PURPOSE: Clinical trial to prevent graft-versus-host disease in patients undergoing bone marrow transplantation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| allogeneic bone marrow transplantation | Procedure | — | UNRESOLVED |
| graft versus host disease prophylaxis/therapy | Biological | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 65 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of one the following: * Acute myelogenous leukemia in CR1, ER1, CR2, ER2, CR3 * Acute lymphocytic leukemia in CR1, ER1, CR2, ER2, CR3 * Non-Hodgkin's lymphoma * Hodgkin's lymphoma * Multiple myeloma with no more than 12 months of prior alkylator based chemotherapy * Myelodysplastic syndrome (MDS) * Acute leukemia arising out of MDS * Primary resistant acute leukemia * Chronic myelomonocytic leukemia * Aplastic anemia (40 years of age and over) * Solid tumor malignancy (germ cell, sarcoma, breast, etc.) * Genetic disorders or inborn errors of metabolism as defined by preparative regimen protocol * Chronic myelogenous leukemia * Must meet all inclusion criteria specified by the respective preparative regimen protocol * No aplastic anemia under 40 years of age or myelofibrosis PATIENT CHARACTERISTICS: Age: * 0.5 to 65 Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Not specified Renal: * Not specified PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior red blood cell or platelet transfusions from a sibling donor Chemotherapy: * Not specified Endocrine therapy: * Not specified Radiotherapy: * Not specified Surgery: * Not specified
References
Publications (1)
- RESULTO'Donnell PV, Jones RJ, Vogelsang GB, Seber A, Ambinder RF, Flinn I, Miller C, Marcellus DC, Griffin C, Abrams R, Braine HG, Grever M, Hess AD, Piantadosi S, Noga SJ. CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies. Bone Marrow Transplant. 1998 Nov;22(10):947-55. doi: 10.1038/sj.bmt.1701476. PMID 9849691